Study of Emu Oil vs. Placebo for Vulvar Pain in Women.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01295268
Recruitment Status : Terminated (enrollment volume due to placebo arm of trial)
First Posted : February 14, 2011
Last Update Posted : January 25, 2017
Information provided by (Responsible Party):
William Beaumont Hospitals

February 10, 2011
February 14, 2011
January 25, 2017
February 2011
August 2011   (Final data collection date for primary outcome measure)
The change in the Global Response Assessment (GRA) for vulvar pain. [ Time Frame: After 1 month of intervention ]
Those "moderately" or "markedly" improved on the GRA are responders
Same as current
Complete list of historical versions of study NCT01295268 on Archive Site
The change in vulvar pain levels [ Time Frame: After 1 month of intervention ]
Based on a pain visual analog scale (VAS) and vulvalgesiometer evaluations.
Same as current
Not Provided
Not Provided
Study of Emu Oil vs. Placebo for Vulvar Pain in Women.
The Efficacy of Emu Oil vs. Placebo in Minimizing Vulvar Pain Levels in Women--A Randomized, Double Blinded, Placebo-Controlled Trial.

The goal of this study is to determine if vulvar (external female genitalia) pain is decreased with emu oil over a similar placebo oil (no active ingredient) by using measurement devices, examinations, and questionnaires. Topical emu oil has not been scientifically studied for this condition yet, but related reports show no significant side effects or potential benefits.

A total of 30 women will participate in the study at William Beaumont Hospital, Royal Oak.

  • Women of all ages with vulvar pain may participate in this trial.
  • Women will be randomized into 2 groups--a treatment group or placebo group for the 1 month study.
  • At the end of the study, those in the placebo group may choose to participate in a 1 month follow-up evaluation using emu oil.
Not Applicable
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Vulvodynia
  • Vestibulodynia
  • Other: Emu Oil
    Subjects will apply a specified amount of emu oil daily to area.
  • Other: Inert oil
    A specified amount of inert oil will be applied daily to area.
  • Active Comparator: Emu Oil
    Intervention: Other: Emu Oil
  • Placebo Comparator: inert oil
    Intervention: Other: Inert oil
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2011
August 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women with vulvar pain upon q-tip exam of > 3/10 at 2 or more sites tested.
  • Age 18 or older.
  • Capable of giving informed consent.
  • Capable and willing to follow all study procedures.

Exclusion Criteria:

  • Pregnant women or those intending to become pregnant during the study period.
  • Vaginitis (may be treated, then tested later).
  • Vulvar disease (other than vulvodynia)—lichen planus, lichen sclerosis, neoplasia, tissue damage due to radiation.
  • The subject is deemed unsuitable for enrollment by the investigators based on their history or physical examination.
  • Neuropathy.
  • Currently in pelvic floor physical therapy.
Sexes Eligible for Study: Female
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
William Beaumont Hospitals
William Beaumont Hospitals
Not Provided
Principal Investigator: Donna J Carrico, WHNP, MS William Beaumont Hospitals
William Beaumont Hospitals
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP